Table 1 Total unadjusted mean resource-use and cost by allocation arm.

From: The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer

 

Active monitoring (n = 513)a

Radiotherapy (n = 516)a

Radical prostatectomy (n = 527)a

 

Mean number of unitsb

Mean cost (£) (SD)

Mean number of unitsb

Mean cost (£) (SD)

Mean number of unitsb

Mean cost (£) (SD)

Hospital outpatients visits

 Procedure-driven appointments

  Protocol radiotherapy

7.77

846 (1608)

28.37

3090 (1665)

3.69

402 (1190)

  Non-protocol radiotherapy

1.01

133 (631)

0.37

49 (377)

1.86

245 (835)

  CT scan

0.29

26 (53)

0.88

81 (56)

0.22

20 (52)

  Radiotherapy preparation

0.27

169 (279)

0.80

503 (252)

0.19

122 (249)

  TRUS

0.35

19 (33)

0.29

16 (30)

0.29

16 (30)

  Trial without a catheter

0.17

24 (57)

0.09

13 (43)

0.53

73 (73)

  Bone scan

0.28

56 (176)

0.11

23 (97)

0.13

26 (102)

  MRI scan

0.20

27 (59)

0.13

17 (53)

0.11

15 (45)

  TRUS-guided biopsy

0.16

35 (83)

0.07

15 (113)

0.04

9 (47)

  Chemotherapy

0.04

58 (663)

0.09

145 (1570)

0.03

50 (844)

  Other procedures

0.50

60 (250)

0.32

57 (346)

0.34

55 (569)

 Speciality-driven appointments

  Urology

8.99

868 (787)

9.56

913 (795)

11.64

1122 (810)

  Oncology

1.08

156 (463)

2.76

400 (646)

1.31

190 (536)

  Uro-oncology

0.62

80 (205)

1.07

137 (235)

0.80

102 (199)

  Other specialitiesc

16.56

912 (519)

4.79

374 (577)

3.98

260 (493)

Total outpatient cost

 

3469 (2754)

 

5832 (3106)

 

2707 (2748)

Hospital day case stays

 Flexible cystoscopy

0.11

51 (165)

0.06

29 (119)

0.08

35 (142)

 Colonoscopy

0.04

21 (126)

0.07

34 (185)

0.02

8 (63)

 TWOC

0.04

16 (83)

0.01

2 (29)

0.05

19 (92)

 Sigmoidoscopy

0.01

5 (46)

0.04

19 (100)

0.02

7 (81)

 Rigid cystoscopy

0.03

27 (160)

0.01

10 (107)

0.04

33 (189)

 TRUS-guided biopsy

0.05

25 (117)

0.01

5 (52)

0.01

4 (46)

 Education

0.02

10 (70)

0.01

4 (52)

0.02

9 (75)

 Chemotherapy

0.01

13 (285)

0.01

21 (390)

0.03

57 (936)

 Urodynamics

0.01

2 (25)

0.01

2 (25)

0.02

6 (43)

 Brachytherapy

0.01

10 (97)

0.01

6 (75)

0.01

6 (75)

 Other day case reasons

0.14

99 (427)

0.12

81 (417)

0.16

119 (505)

Total day case cost

 

277 (689)

 

214 (715)

 

303 (1299)

Hospital inpatient stays

 Prostatectomy

0.25

1332 (2380)

0.11

578 (1709)

0.77

4013 (2347)

 Infection

0.02

31 (278)

0.02

42 (721)

0.04

76 (509)

 TURP

0.05

142 (667)

0.02

44 (333)

0.00

21 (379)

 Brachytherapy

0.03

61 (347)

0.02

32 (240)

0.02

31 (237)

 Bladder neck procedure

0.01

18 (213)

0.01

30 (278)

0.02

44 (443)

 Insertion of urinary sphincter

0.01

129 (1238)

0.01

70 (796)

0.02

206 (1464)

 Pain

0.01

17 (243)

0.01

10 (115)

0.02

28 (323)

 Urinary retention

0.01

17 (143)

0.01

7 (94)

0.01

14 (131)

 Rigid cystoscopy

0.00

3 (60)

0.01

19 (158)

0.01

16 (168)

 Blood transfusion

0.02

18 (255)

0.00

0 (0)

0.00

4 (90)

 Other inpatient stays

0.15

434 (2298)

0.08

235 (1458)

0.18

403 (2316)

Total inpatient cost

 

2202 (3956)

 

1068 (2854)

 

4855 (4055)

GP practice visits

 By healthcare professional

  GP

0.81

36 (79)

0.93

41 (86)

1.09

48 (92)

  GP nurse

0.91

13 (38)

0.66

10 (34)

0.69

10 (36)

  Other

0.05

1 (5)

0.07

1 (9)

0.12

2 (16)

 By reason

  PSA test

27.41

435 (142)

20.91

332 (140)

20.80

330 (138)

  Hormone delivery

1.97

44 (146)

4.24

94 (87)

0.85

19 (87)

Total GP practice cost

 

528 (243)

 

477 (205)

 

409 (231)

Medications

 Cyproterone acetate daysd

0.23

1 (5)

0.37

1 (7)

0.16

0 (4)

 Hormone injections

2.48

277 (770)

3.96

331 (515)

1.20

154 (606)

Total medication cost

 

277 (770)

 

332 (515)

 

154 (606)

Total cost

 

6754 (5597)

 

7923 (4717)

 

8428 (5636)

  1. aGiven the missing data assumptions (Supplementary Table 2), resource-use was obtained for 1556 (95%) of the 1653 men randomised into the ProtecT study.
  2. bUnits refer as appropriate to: number of outpatient appointments; number of day case visits; number of inpatient stays; number of GP practice visits; number of medications; number of days.
  3. cIncludes Accident and Emergency visits that did not lead to a procedure costed by the HRG.
  4. dAssuming a daily dose of 200 mg.